| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
- Bufotalin acts on endoplasmic reticulum (ER) stress-related signaling pathways in osteoblastoma cells [1]
- Bufotalin targets G2/M cell cycle regulatory proteins in multidrug-resistant HepG2 (MDR-HepG2) cells [2] |
|---|---|
| ln Vitro |
Bufotalin (0.1-2.5 μM; 12-96 hours) treatment dose- and time-dependently inhibits MG-63 osteoblastoma cell survival[1].
Bufotalin (0.5-2.5 μM; 48 hours) treatment increases the percentage of Annexin V positive cells (apoptotic cells) and caspase-12 activity in MG-63 cells in a dose-dependent manner. Caspase-12 activation is linked to bufotalin-induced osteoblastoma cell apoptosis[1]. Bufotalin (0.5-2.5 μM; 12 hours) treatment dose-dependently induces C/EBP homologous protein (CHOP) expression as well as PERK and IRE1 phosphorylation in MG-63 cells. Bufotalin causes cells to activate their ER under stress[1]. Bufotalin treatment causes cell cycle arrest at G2/M phase in HepG2 cells by up-regulating p53 and p21 and down-regulating Aurora A, CDC25, CDK1, cyclin A, and cyclin B1. Bufotalin treatment also causes apoptosis, which was accompanied by alterations in the expression of bcl-2 and bax as well as changes in the levels of intracellular calcium and reactive oxygen species as well as activations of caspase-9 and -3. - For osteoblastoma cells: Treatment with Bufotalin (concentration range: 0.1–1 μM) induced dose-dependent apoptosis, accompanied by upregulated expression of ER stress markers (GRP78, CHOP, cleaved caspase-12) detected via western blot; the IC50 for apoptotic induction was ~0.5 μM [1] - For MDR-HepG2 cells: Bufotalin (concentration range: 0.01–1 μM) inhibited cell proliferation in a dose-dependent manner (IC50: ~0.2 μM), caused G2/M cell cycle arrest (confirmed by flow cytometry), and induced apoptosis with upregulated Bax and downregulated Bcl-2 (detected via western blot) [2] |
| ln Vivo |
Bufotalin (0.5-1 mg/kg; intraperitoneal injection; twice daily; for 7 days) treatment intraperitoneal injection) significantly slows the growth of tumors in mice[1].
|
| Cell Assay |
- Osteoblastoma cell experiment: Cells were seeded and treated with Bufotalin at concentrations of 0.1, 0.5, and 1 μM for 24–48 hours. Apoptosis was detected using Annexin V-FITC/PI double staining combined with flow cytometry; ER stress markers (GRP78, CHOP, cleaved caspase-12) were analyzed through western blot (including protein extraction, SDS-PAGE, membrane transfer, antibody incubation, and chemiluminescence detection) [1]
- MDR-HepG2 cell experiment: Cells were cultured and exposed to Bufotalin at concentrations of 0.01, 0.1, 0.5, and 1 μM for 24–72 hours. Cell proliferation was measured via CCK-8 assay (detecting absorbance at 450 nm); cell cycle distribution was analyzed by flow cytometry after PI staining; apoptosis-related proteins (Bax, Bcl-2) were detected using western blot [2] |
| References |
|
| Additional Infomation |
Bufotalin is a steroidal lactone whose function is related to Bufotalin.
Bufotalin has been reported to exist in African toads (Phrynoidis asper), African toads (Bufo gargarizans), and other organisms with relevant data. - The endoplasmic reticulum stress inhibitor 4-phenylbutyric acid (4-PBA) can partially reverse Bufotalin-induced osteoblastoma cell apoptosis, confirming that endoplasmic reticulum stress activation is the key mechanism by which it induces apoptosis[1]. - Bufotalin is isolated from toads (Venenum bufonis), and its inhibitory effect on MDR-HepG2 cells is not affected by P-glycoprotein (a key mediator of multidrug resistance)[2]. |
| Molecular Formula |
C26H36O6
|
|---|---|
| Molecular Weight |
444.5604
|
| Exact Mass |
444.251
|
| CAS # |
471-95-4
|
| Related CAS # |
471-95-4
|
| PubChem CID |
12302120
|
| Appearance |
White to off-white solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
591.7±50.0 °C at 760 mmHg
|
| Melting Point |
223°C (rough estimate)
|
| Flash Point |
195.8±23.6 °C
|
| Vapour Pressure |
0.0±3.8 mmHg at 25°C
|
| Index of Refraction |
1.587
|
| LogP |
2.54
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
878
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
O([H])[C@]12C([H])([H])[C@@]([H])([C@]([H])(C3=C([H])OC(C([H])=C3[H])=O)[C@@]1(C([H])([H])[H])C([H])([H])C([H])([H])[C@]1([H])[C@@]3(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[C@@]3([H])C([H])([H])C([H])([H])[C@@]21[H])O[H])OC(C([H])([H])[H])=O
|
| InChi Key |
VOZHMAYHYHEWBW-NVOOAVKYSA-N
|
| InChi Code |
InChI=1S/C26H36O6/c1-15(27)32-21-13-26(30)20-6-5-17-12-18(28)8-10-24(17,2)19(20)9-11-25(26,3)23(21)16-4-7-22(29)31-14-16/h4,7,14,17-21,23,28,30H,5-6,8-13H2,1-3H3/t17-,18+,19+,20-,21+,23+,24+,25-,26+/m1/s1
|
| Chemical Name |
[(3S,5R,8R,9S,10S,13R,14S,16S,17R)-3,14-dihydroxy-10,13-dimethyl-17-(6-oxopyran-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate
|
| Synonyms |
Bufotalin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~224.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2494 mL | 11.2471 mL | 22.4942 mL | |
| 5 mM | 0.4499 mL | 2.2494 mL | 4.4988 mL | |
| 10 mM | 0.2249 mL | 1.1247 mL | 2.2494 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
